What is Johnson & Johnson's financial performance in the latest quarter?

Johnson & Johnson reported a 20.8% increase in net earnings to $5.12 billion for the latest quarter, driven by strong sales of newer drugs.

How is J&J compensating for the Stelara patent loss?

J&J is offsetting the sales decline from the Stelara patent loss with strong growth from newer cancer and autoimmune drugs like Darzalex and Tremfya.

What is Johnson & Johnson's forecast for 2026?

J&J forecasts over 6% sales growth and adjusted earnings per share of $11.53 for 2026, exceeding Wall Street expectations.

Home / Business and Economy / J&J Surges Past Patent Loss with New Drug Strength

J&J Surges Past Patent Loss with New Drug Strength

21 Jan

•

Summary

New drug sales offset Stelara patent loss, boosting revenue.
Company forecasts exceeding Wall Street expectations for 2026.
Fourth-quarter net earnings rose 20.8% to $5.12 billion.

J&J Surges Past Patent Loss with New Drug Strength

Johnson & Johnson has announced robust financial results for the latest quarter, with higher sales of drugs for cancer and autoimmune conditions significantly offsetting the impact of a key patent expiration. This strategic growth has led to increased revenue and profit for the company.

In the fourth quarter, net earnings rose by 20.8% to $5.12 billion. While the company experienced a nearly 48% plunge in sales for its former blockbuster drug Stelara due to competitor versions, newer treatments like Darzalex and Tremfya demonstrated substantial growth, with sales up nearly 27% and 68% respectively.

The company also provided an optimistic forecast for the upcoming year, projecting sales growth exceeding 6% and earnings per share of $11.53 on an adjusted basis. This outlook was issued despite anticipated impacts from tariffs and a recent agreement to reduce certain drug prices, indicating J&J's resilience and confidence in its pipeline.